3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
2
Terminated
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Conditions
Thrombocythemia, Essential
1
Myeloproliferative Disorders
1
Interventions
pembrolizumab
436
Carboplatin
321
Nivolumab
287
Cyclophosphamide
280
Specimen Handling
257
Cisplatin
251
Paclitaxel
248
Magnetic Resonance Spectroscopy
248
Radiotherapy
217
Gemcitabine
180
Dexamethasone
180
Biopsy
177
durvalumab
166
atezolizumab
148
Rituximab
138
Lenalidomide
134
Doxorubicin
134
Docetaxel
130
Bevacizumab
129
Ipilimumab
125
Radiation
118
Capecitabine
117
Pemetrexed
112
Oxaliplatin
112
Etoposide
111
Radiosurgery
108
Fluorouracil
108
venetoclax
106
fludarabine
106
Prednisone
97
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Interventional
×
anagrelide
×
Clear all
NCT04285086
2025-08-13
SURPASS ET
PharmaEssentia
Phase 3
Active not recruiting
174 enrolled